Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data-Reference-Cited by-同舟云学术

Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data

Published:2020-02-26 Issue:10 Volume:45 Page:1298-1301
ISSN:0271-3683
Container-title:Current Eye Research
language:en
Short-container-title:Current Eye Research

Author:

Agostini Hansjürgen¹,Mulyukov Zufar²,Tsilimbaris Miltiadis³,Calvo Pilar⁴,Bucher Felicitas¹,Gaucher David⁵,Pigeolet Etienne²,Colafrancesco Valeria⁶,Clemens Andreas²⁷

Affiliation:

1. Eye Center, Medical Center, Faculty of Medicine, University of Freiburg , Freiburg, Germany

2. Novartis Pharma AG , Basel, Switzerland

3. Department of Ophthalmology, University Hospital of Heraklion , Heraklion, Greece

4. IIS-Aragon, Department of Ophthalmology, Miguel Servet University Hospital , Zaragoza, Spain

5. Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg , Strasbourg, France

6. Novartis Farmaceutica, SA , Barcelona, Spain

7. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg , Freiburg, Germany

Funder

Novartis Pharmaceuticals Corporation

Publisher

Informa UK Limited

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://www.tandfonline.com/doi/pdf/10.1080/02713683.2020.1731832

Reference22 articles.

1. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

2. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

5. Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis;PeerJ;2024-06-21

2. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration;PLOS ONE;2024-04-18

3. Laser flare photometry in eyes receiving brolucizumab intravitreal injections for age related macular degeneration;European Journal of Ophthalmology;2024-03-06

4. Short-term outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration;2023-09-15

5. RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS;Retina;2022-11